Search
Paroxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigationalParoxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. … [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine, (−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidineAgkistrodon piscivorus antivenin
go.drugbank.com/drugs/DB13894ApprovedThe cottonmouth, Agkistrodon piscivorus, is a large, venomous snake in the pit viper subfamily (Crotalinae). … This species of snake is endemic to the United States.
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigationalSotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type … 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalAprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan]. … blocker, and a diuretic at maximally tolerated doses.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2C18 InhibitorsIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid, BORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. … It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexUbrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigationalUbrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesViloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnViloxazine is a selective norepinephrine reuptake inhibitor.[L41685] For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-((2-Ethoxyphenoxy)methyl)morpholineCobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTASResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalResmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 1,2,4-Triazine-6-carbonitrile, 2-[3,5-dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-, 2-[3,5-Dichloro-4-[[1,6-dihydro-5-(1-methylethyl)-6-oxo-3-pyridazinyl]oxy]phenyl]-2,3,4,5-tetrahydro-3,5-dioxo-1,2,4-triazine-6-carbonitrile